VistaGen Therapeutics, Inc.VTGNNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Loading chart...

Alerts

Want to monitor VTGN?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Create free account to monitor VTGN

Key Statistics

About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets.

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

www.vistagen.com →

Alerts

Key Statistics

About

News

Take-Two added to Wedbush's Best Ideas List on strong franchise moat, GTA VI potential

PayPal to Report Q4 Earnings: What Should Investors Do?

Imperial Oil Q4 Earnings Surpass Estimates, Revenues Miss

YUM to Post Q4 Earnings: What's in the Cards for the Stock?

Essity completes the acquisition of Edgewell's feminine care business

Telia, Lyse to combine Norwegian mobile radio networks to save costs

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ramaco Resources, Inc. (METC)

CRA (CRAI) Moves 5.9% Higher: Will This Strength Last?

Are You Looking for a High-Growth Dividend Stock?

Morgan Stanley (MS) Could Be a Great Choice

First Mid Bancshares (FMBH) Could Be a Great Choice

Home BancShares (HOMB) Could Be a Great Choice

Are You Looking for a High-Growth Dividend Stock?

Why Cullen/Frost Bankers (CFR) is a Top Dividend Stock for Your Portfolio

Why Tompkins Financial (TMP) is a Great Dividend Stock Right Now

3 Stocks Trump Could Back Next as USA Rare Earths Revives the Federal Catalyst Trade

ManpowerGroup Stock Rises 9.1% Since Q4 Earnings and Revenue Beat

DAKT vs. GRMN: Which Stock Is the Better Value Option?

TTDKY vs. OSIS: Which Stock Is the Better Value Option?

NEXA vs. TECK: Which Stock Is the Better Value Option?

Explore More

Take-Two added to Wedbush's Best Ideas List on strong franchise moat, GTA VI potential

PayPal to Report Q4 Earnings: What Should Investors Do?

Imperial Oil Q4 Earnings Surpass Estimates, Revenues Miss

YUM to Post Q4 Earnings: What's in the Cards for the Stock?

Essity completes the acquisition of Edgewell's feminine care business

Telia, Lyse to combine Norwegian mobile radio networks to save costs

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Ramaco Resources, Inc. (METC)

CRA (CRAI) Moves 5.9% Higher: Will This Strength Last?

Are You Looking for a High-Growth Dividend Stock?

Morgan Stanley (MS) Could Be a Great Choice

First Mid Bancshares (FMBH) Could Be a Great Choice

Home BancShares (HOMB) Could Be a Great Choice

Are You Looking for a High-Growth Dividend Stock?

Why Cullen/Frost Bankers (CFR) is a Top Dividend Stock for Your Portfolio

Why Tompkins Financial (TMP) is a Great Dividend Stock Right Now

3 Stocks Trump Could Back Next as USA Rare Earths Revives the Federal Catalyst Trade

ManpowerGroup Stock Rises 9.1% Since Q4 Earnings and Revenue Beat

DAKT vs. GRMN: Which Stock Is the Better Value Option?

TTDKY vs. OSIS: Which Stock Is the Better Value Option?

NEXA vs. TECK: Which Stock Is the Better Value Option?

Key Statistics